PPARγ agonist 20
PPARγ agonist 20 is a potent, orally active PPAR-γ agonist. PPARγ agonist 20 effectively increases antioxidant defenses (SOD, GSH) and reduces lipid peroxidation. PPARγ agonist 20 can upregulate of Pparg, Glut4, and AdipoQ, suppresses of TNF-α, IL-6, and NF-κB p65. PPARγ agonist 20 significantly lowers fasting blood glucose, improving glucose tolerance, and restoring metabolic balance in Streptozotocin (HY-13753)-Nicotinamide (HY-B0150)-induced diabetic rats. PPARγ agonist 20 can be used for the study of type 2 diabetes.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- 화학식: C25H20ClN5O5S
- 분자량:537.97
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
PPARγ agonist 20 (Compound 7e) (6.25-100 μM) induces a significantly high expression of PPAR-γ in HepG2 cells and L6 myotubes[1].
PPARγ agonist 20 exhibits good inhibitory activity against α-amylase (IC50 = 23.3 μg/mL) and α-glucosidase (IC50 = 21.1 μg/mL)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | T1/2 | Tmax | Cmax | AUC0-inf | AUC0-t |
|---|---|---|---|---|---|---|---|
| Rat | 50 mg/kg | p.o. | 4 h | 3 h | 2.069 μg/mL | 13.04 μg·h/mL | 11.87 μg·h/mL |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:A single intraperitoneal dose of STZ (45 mg/kg body weight), administered 20 min after intraperitoneal injection of nicotinamide (110 mg/kg body weight), resulted in the induction of type 2 diabetes mellitus in the male Wistar rats (160.23 ± 10.00 g)[1].
-
Dosage:50 mg/kg
-
Administration:P.o., once daily for 28 days
-
Result:Led to a significant and dose-dependent improvement in body weight, and mitigated diabetes-associated muscle wasting and metabolic decline.
Effectively controlled hyperglycemia by enhancing insulin sensitivity and glucose handling.
Significantly reduced serum alanine aminotransferase (SGPT), serum aspartate aminotransferase (SGOT), and alkaline phosphatase (ALP) levels.
Significantly reduced the levels of urea, creatinine, and uric acid.
Significantly improved lipid profile: reduced TG, TC, LDL, and VLDL, and increased HDL.
Upregulated metabolic genes (Pparg, Glut4, AdipoQ) and downregulated inflammatory genes (TNF-α, IL-6).
Increased PPAR-γ protein expression and inhibited NF-κB p65.
Reversed tissue damage caused by diabetes, including adipose tissue, pancreas, liver, and skeletal muscle.
Chemical Information
-
분자량 537.97
-
화학식 C25H20ClN5O5S
-
SMILES
COC1=CC(/C=N/NC(N/N=C/C2=CC=C(C(O)=C2O)O)=S)=CC=C1OC3=CC=NC4=CC(Cl)=CC=C43
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PPARγ agonist 20 Related Classifications
HY-178447 Related Classifications
Powered by Bioz